Major breakthroughs in the field of chronic heart failure
JK07 is an NRG-1 (Neuregulin-1) fusion antibody drugwhich is independently developed by Salubris Biotherapeutics Inc. and hasindependent intellectual property rights in major countries/regions around theworld. The indication to be developed is chronic heart failure.
Salubris received the Notice of Approval of Clinical Trials from National Medical Products Administration, which grants Salubris to carry out clinical trials with " Recombinant fusion protein consisting of a fully human immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1".
SAL007 was approved by the FDA in February 2020 for its first clinical trial. The head clinical research institute of clinical phase I in US is Cleveland Clinic, and currently the trial is recruiting participants.
Salubris Biotherapeutics, Inc., a wholly owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd., submitted a clinical application for SAL007 to FDA on January 23, 2020, and was successfully approved on February 22.
Cardiovascular disease is still the first cause of death in the world. Currently, there are about 26 million patients with heart failure in the world, including about 13.7 million patients in China and about 6.5 million patients in the United States